Role of HIV on Glutathione Synthesis and Oxidative Stress

Last updated: February 5, 2013
Sponsor: Baylor College of Medicine
Overall Status: Completed

Phase

1

Condition

Hiv/aids

Aids And Aids Related Infections

Hiv Infections

Treatment

N/A

Clinical Study ID

NCT01355198
HIV and glutathione
  • Ages 21-70
  • Male

Study Summary

HIV infection is associated the development of increased oxidative stress and deficiency of glutathione (GSH), the dominant endogenous antioxidant protein, but the underlying mechanisms contributing to GSH deficiency are hitherto unknown. Furthermore GSH metabolism has not been studied in HIV patients, in whom the burden of risk factors promoting oxidative stress is highest. Our previous studies in non-HIV human subjects with diabetes-related oxidative stress and GSH deficiency have demonstrated that the latter is due to decreased synthesis of GSH. Importantly, short-term dietary supplementation with the simple GSH precursor amino-acids cysteine and glycine, boosted GSH synthesis and cellular concentrations, corrected GSH deficiency, and reduced oxidative stress and oxidant damage. The current proposal will study whether (1) defective synthesis underlies GSH deficiency in patients with HIV, and will test a simple, inexpensive and rational therapy based on protein supplementation to improve GSH synthesis and concentrations and lower markers of oxidative stress and oxidant damage in these patients; (2) study if correction of GSH deficiency is asssociated with any changes in (a) impaired mitochondrial fuel oxidation in the fasted and insulin stimulated states; (b) insulin sensitivity; (c) body composition and anthropometry; (d) forearm muscle strength; (e) plasma biochemistry, and (f) quality of life indices in these subjects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

(1) HIV infected patients with GSH deficiency

Exclusion

Exclusion Criteria:

  1. renal impairment (serum Creatinine above 1.5mg/dL), liver impairment (ALT and AST > 2xupper limit of normal)

  2. any hormonal disorders such as hypothyroidism, hypercortisolemia, hypogonadism, ordiabetes mellitus on pharmacotherapy

  3. evidence of infections other than HIV in the preceding 3 months

  4. subjects with plasma triglyceride concentrations of ≥ 500mg/dL on triglyceridelowering therapy

  5. BMI < 20

  6. established heart disease

  7. Co-existing viral hepatitis B and C

Study Design

Total Participants: 10
Study Start date:
August 01, 2010
Estimated Completion Date:
September 30, 2011

Connect with a study center

  • Baylor GCRC

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.